| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T181 |
0-17 |
Sentence |
denotes |
6.2.2 Rationale: |
| T182 |
18-97 |
Sentence |
denotes |
Tocilizumab can treat lung injury in patients with critical and severe COVID-19 |
| T183 |
98-245 |
Sentence |
denotes |
In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. |
| T184 |
246-464 |
Sentence |
denotes |
Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. |
| T185 |
465-523 |
Sentence |
denotes |
Also, lung lesion opacity was absorbed in 90% of patients. |
| T186 |
524-603 |
Sentence |
denotes |
Neither serious adverse effects nor deaths occurred with tocilizumab treatment. |
| T187 |
604-710 |
Sentence |
denotes |
There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19. |
| T188 |
711-926 |
Sentence |
denotes |
Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28]. |
